Valion Bio, Inc.
VBIO· Nasdaq
VBIOValion Bio, Inc.
Filed May 15, 2023 · 10-Q · 45 days after period end · 0000950170-23-022256
| Metric | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|
| Revenue | $376.00K | $428.00K | $323.00K |
| Net Income | -$2.12M | -$2.24M | -$1.36M |
| EPS Diluted | -$10.52 | -$0.23 | -$0.58 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end
